TB Alliance Welcomes Drug-Resistant TB Survivors to Access Advisory Committee
NEW YORK (March 24, 2021)—TB Alliance is excited to announce the expansion of its Access Advisory Committee (AAC) to include
Access News
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
New Clinical Access Program to Expand Access to Tuberculosis Treatment Pretoria, 10 December 2020—TB Alliance welcomes the Wits Health Consortium
TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder
One Year Since U.S. Approval, Accelerating Access to New TB Therapy
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL
TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for New Highly Resistant TB Treatment
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet
TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned
TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to